Primary Hypothesis: Levodopa-induced dyskinesias (LID) result from dysregulated dopamine receptor signaling in the striatum due to chronic non-physiological dopamine replacement, leading to abnormal striatal plasticity and hyper-excitable cortico-striatal circuits.
Secondary Hypotheses:
- Pulsatile dopamine receptor activation from oral levodopa triggers downstream signaling cascades (ERK, mTOR, DARPP-32) that promote aberrant synaptic plasticity
- Genetic variants in dopamine metabolism and receptor genes modify LID susceptibility
- Baseline alpha-synuclein burden in the striatum correlates with LID severity
This experiment addresses the critical knowledge gap identified in the PD Cure Roadmap:
- Gap #15: What causes levodopa-induced dyskinesias and how can they be prevented? (27 pts)
- Gap #12: What is the relationship between striatal alpha-synuclein and treatment response?
- Type: Prospective longitudinal cohort with experimental arm
- Cohort:
- PD patients with motor fluctuations (n=200): Newly initiated on levodopa, followed prospectively
- PD patients without dyskinesias (n=50): Stable levodopa responders, disease-matched controls
- PD patients with established LID (n=50): Cross-sectional comparison
- Follow-up: 24 months from levodopa initiation
- Idiopathic Parkinson's disease (UK Brain Bank criteria)
- Motor fluctuations (≥1 hour "off" time/day) OR newly diagnosed, levodopa-naive
- Age 40-80 years
- MMSE ≥24
- Stable antiparkinsonian medications for ≥4 weeks before enrollment
- Atypical parkinsonism (PSP, MSA, CBS)
- Prior deep brain stimulation
- Active psychiatric disorder (DSM-V criteria)
- Contraindications to lumbar puncture or MRI
| Assessment |
Frequency |
Purpose |
| MDS-UPDRS Parts I-IV |
Monthly |
Motor and non-motor symptoms |
| Rush Levodopa-Induced Dyskinesias Rating Scale |
Monthly |
LID severity scoring |
| Hauser Diary (4-day) |
Every 3 months |
"On"/"Off" time quantification |
| NMSS (Non-Motor Symptom Scale) |
Every 3 months |
Non-motor burden |
| PDQ-39 |
Every 3 months |
Quality of life |
-
CSF Collection (baseline, 12mo, 24mo):
- Dopamine metabolites (HVA, DOPAC)
- Alpha-synuclein species (total, phosphorylated, oligomeric)
- Inflammatory markers (IL-6, TNF-alpha, CRP)
- Neurogranin (synaptic marker)
- Neurofilament light chain (NfL)
-
Blood Collection (monthly):
- Complete blood count, metabolic panel
- Genotyping panel (COMT, DAT, DRD2, DRD3, ANKK1)
- Inflammatory markers
-
Imaging (baseline, 12mo, 24mo):
- DaTscan (123I-ioflupane) for dopaminergic terminal integrity
- MR spectroscopy of striatum (GABA, glutamate)
- Resting-state fMRI for cortico-striatal connectivity
- Model System: Mouse models (C57BL/6, BAC GFP-LRRK2 G2019S, Synuclein preformed fibril)
- Intervention: Chronic levodopa/benserazide administration (equivalent to human 5 years exposure)
- Readouts:
- Behavioral: Cylinder test, apomorphine-induced rotation, detailed dyskinesia scoring
- Molecular: Western blot, phospho-proteomics of striatum
- Electrophysiology: Ex vivo striatal slice recordings
| Intervention |
Rationale |
Arm Size |
| Continuous dopaminergic stimulation (CDS) via rodent |
Test whether continuous vs pulsatile delivery prevents LID |
n=30 mice |
| Amantadine (NMDA antagonist) |
Test whether acute blockade prevents chronic dyskinesias |
n=30 mice |
| DRD1 antagonist (SCH-23390) pre-treatment |
Test whether D1 receptor blockade during levodopa induction prevents LID |
n=30 mice |
| mTOR inhibitor (rapamycin) |
Test whether mTOR signaling inhibition prevents aberrant plasticity |
n=30 mice |
- Source: Post-mortem brain tissue from PD patients with/without LID (n=20 each)
- Regions: Putamen, caudate, motor cortex
- Assays:
- Immunohistochemistry for phosphorylated DARPP-32, ERK1/2
- qPCR for dopamine receptor isoforms
- proteomics for synaptic proteins
- Incidence of LID at 24 months: Expected 30-40% of continuously treated patients
- Time to LID onset: Median 18 months (range 6-36 months)
- Biomarker signature predictive of LID: Identify combination of baseline biomarkers with >80% sensitivity
- Genetic risk score: Identify variants with >2-fold LID risk
- Mechanistic validation: Confirm role of ERK/mTOR/DARPP-32 signaling in mouse models
- Preventive intervention efficacy: Identify at least one intervention that reduces LID incidence by >50%
- Alpha-synuclein correlation: Determine if baseline CSF alpha-synuclein burden predicts LID severity
- Striatal connectivity biomarkers: Identify fMRI-based predictors of LID risk
- Sex differences: Characterize potential sex-based differences in LID susceptibility
- Multi-center design ensures adequate enrollment (rare disease subgroup)
- Longitudinal design captures temporal dynamics
- Integration of human cohorts with mechanistic mouse studies
- Comprehensive biomarker panel enables multi-omics discovery
- Long follow-up period (24 months) may lead to attrition
- Mouse model validity (do they fully recapitulate human LID?)
- CSF collection may limit enrollment (patient acceptance)
- Genetic heterogeneity in PD populations
| Milestone |
Expected Date |
| Protocol finalization |
Month 1-2 |
| IRB approval and site activation |
Month 3-4 |
| First patient enrolled |
Month 5 |
| 50% enrollment |
Month 12 |
| Full enrollment |
Month 18 |
| Primary analysis |
Month 30 |
| Publication |
Month 36 |
| Category |
Cost (USD) |
| Personnel (2 FTE coordinators, 1 PI, 1 biostatistician) |
$1,200,000 |
| Clinical assessments and procedures |
$400,000 |
| Biomarker assays (CSF, blood, imaging) |
$600,000 |
| Mouse study (4 arms, n=30 each) |
$200,000 |
| Tissue banking and pathology |
$150,000 |
| Data management and statistics |
$100,000 |
| Indirect costs (20%) |
$530,000 |
| Total |
$3,180,000 |
This experiment has broader implications for:
- Dystonia mechanisms (shared basal ganglia dysfunction)
- Tardive dyskinesia (antipsychotic-induced movement disorder)
- Other dopamine replacement therapies (apomorphine, rotigotine)
- Neurodegeneration (understanding dopamine-dependent plasticity)